Insufficient scRNA-seq data for expression of CYP26A1 at single-cell level.
Insufficient scRNA-seq data for expression of CYP26A1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 97% | 774.23 | 219 / 226 | 15% | 0.54 | 62 / 406 |
spleen | 94% | 18.99 | 227 / 241 | 0% | 0 | 0 / 0 |
brain | 78% | 35.88 | 2058 / 2642 | 3% | 0.10 | 24 / 705 |
breast | 55% | 35.23 | 254 / 459 | 23% | 0.69 | 262 / 1118 |
lung | 53% | 6.63 | 307 / 578 | 23% | 2.23 | 267 / 1155 |
uterus | 59% | 12.99 | 101 / 170 | 17% | 1.21 | 77 / 459 |
adrenal gland | 44% | 9.94 | 113 / 258 | 20% | 1.75 | 46 / 230 |
ovary | 41% | 6.09 | 73 / 180 | 13% | 0.33 | 55 / 430 |
skin | 35% | 5.25 | 629 / 1809 | 14% | 0.74 | 66 / 472 |
thymus | 40% | 3.67 | 262 / 653 | 6% | 0.38 | 36 / 605 |
prostate | 42% | 4.76 | 103 / 245 | 2% | 0.10 | 11 / 502 |
adipose | 43% | 7.82 | 519 / 1204 | 0% | 0 | 0 / 0 |
kidney | 38% | 4.26 | 34 / 89 | 2% | 0.28 | 19 / 901 |
tonsil | 0% | 0 | 0 / 0 | 36% | 1.96 | 16 / 45 |
esophagus | 11% | 1.34 | 163 / 1445 | 22% | 2.55 | 41 / 183 |
pancreas | 14% | 0.97 | 45 / 328 | 17% | 0.53 | 30 / 178 |
intestine | 25% | 2.59 | 245 / 966 | 4% | 0.12 | 22 / 527 |
bladder | 19% | 1.57 | 4 / 21 | 6% | 0.50 | 31 / 504 |
peripheral blood | 24% | 3.42 | 220 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 20% | 8.50 | 261 / 1335 | 0% | 0 | 0 / 0 |
muscle | 14% | 1.44 | 115 / 803 | 0% | 0 | 0 / 0 |
stomach | 8% | 0.62 | 28 / 359 | 3% | 0.06 | 10 / 286 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.18 | 2 / 29 |
heart | 7% | 0.89 | 56 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.06 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006766 | Biological process | vitamin metabolic process |
GO_0001822 | Biological process | kidney development |
GO_0033189 | Biological process | response to vitamin A |
GO_0048387 | Biological process | negative regulation of retinoic acid receptor signaling pathway |
GO_0016125 | Biological process | sterol metabolic process |
GO_0042573 | Biological process | retinoic acid metabolic process |
GO_0032526 | Biological process | response to retinoic acid |
GO_0034653 | Biological process | retinoic acid catabolic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0016709 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen |
GO_0062183 | Molecular function | all-trans retinoic acid 18-hydroxylase activity |
GO_0062182 | Molecular function | all-trans retinoic acid 4-hydrolase activity |
GO_0019825 | Molecular function | oxygen binding |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008401 | Molecular function | retinoic acid 4-hydroxylase activity |
GO_0020037 | Molecular function | heme binding |
GO_0001972 | Molecular function | retinoic acid binding |
Gene name | CYP26A1 |
Protein name | Cytochrome P450 family 26 subfamily A member 1 Cytochrome P450 26A1 (CYP26A1) (EC 1.14.13.-) (Cytochrome P450 retinoic acid-inactivating 1) (Cytochrome P450RAI) (hP450RAI) (Retinoic acid 4-hydroxylase) (Retinoic acid-metabolizing cytochrome) |
Synonyms | CYP26 P450RAI1 |
Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals . RAs exist as at least four different isomers: all-trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the hydroxylation of atRA primarily at C-4 and C-18, thereby contributing to the regulation of atRA homeostasis and signaling . Hydroxylation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination (Probable). Involved in the convertion of atRA to all-trans-4-oxo-RA. Able to metabolize other RAs such as 9-cis, 13-cis and 9,13-di-cis RA (By similarity) . Can oxidize all-trans-13,14-dihydroretinoate (DRA) to metabolites which could include all-trans-4-oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all-trans-18-hydroxy-DRA (By similarity). May play a role in the oxidative metabolism of xenobiotics such as tazarotenic acid . . |
Accessions | ENST00000371531.5 [O43174-2] ENST00000624589.3 O43174 ENST00000224356.5 [O43174-1] A0A096LNN2 |